Prometic presents PBI-4050’s positive effect on diabetic patients’ kidneys at the American Society of Nephrology annual meeting

November 18, 2016 Fred Dumais

LAVAL, QUEBEC, CANADA, – November 18, 2016 – ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF)(“ProMetic” or the “Corporation”) today announced that it is presenting new data at the American Society of Nephrology’s (“ASN”) Annual Meeting currently underway in Chicago, with respect to ProMetic’s anti-fibrotic and orally active lead drug candidate, PBI-4050.

“We have several presentations at this year’s ASN meeting providing further substantial evidence of PBI-4050’s ability to reduce kidney and pancreatic fibrosis and preserve their respective functions”, stated Mr. Pierre Laurin, President and Chief Executive Officer of ProMetic. “This year, we are also presenting data on the positive effect of PBI-4050 on the kidneys of patients suffering from metabolic syndrome and type 2 diabetes (“MST2D”), evidenced by the significant reduction of biomarkers in urine.  PBI-4050’s performance in a myriad of preclinical renal models and in our phase 2 clinical trial in MST2D patients gives us great confidence for the forthcoming clinical trial in patients with Chronic Kidney Disease, which we plan to initiate early next year”, added Mr. Laurin.

Clinical Poster Presentation

PBI-4050 reduces Cardiovascular and Renal Biomarkers in Type II Diabetic Patients with Metabolic Syndrome (Abstract #6341)

Preclinical Poster Presentation

PBI-4050 Protects Against Renal Fibrosis and Improves Pancreatic Function in High Fat Diet db/db Mouse Model (Abstract #2441)

Oral Treatment with PBI-4050 Reduces Kidney Fibrosis (Abstract #4867)

Oral Treatment with PBI-4050, a Novel Anti-Diabetic and Anti-Fibrotic Compound, Reduces Renal and White Adipose Tissue Fibrosis in ob/ob Mice (Abstract #4889)

PBI-4425, a Novel Anti-Inflammatory/Fibrotic Compound, Improves Kidney Function in 5/6-Nephrectomized Rats (Abstract #4922)

Oral Treatment with PBI-4547, a Novel Anti-Diabetic and Anti-Fibrotic Compound, Reduces Blood Glucose and Renal Fibrosis in ob/ob Mice (Abstract #4938)

Treatment Efficacy of PBI-4050, an Orally Active Anti-Fibrotic Agent, Can Be Monitored by Measuring Urinary Biomarkers in 5/6-Nephrectomized Rats (Abstract #4946)

Late Intervention with PBI-4050 Offers Renoprotection in a Mouse Model of Renin-Dependent/Streptozotocin-Induced Nephropathy (Abstract #4973)

More About PBI-4050

PBI-4050 is an orally active lead drug candidate with excellent safety and efficacy profiles confirmed in several in vivo experiments targeting fibrosis. Fibrosis is a very complex process by which continuing inflammation causes vital organs to lose their function as normal tissue is replaced by fibrotic scar tissue. The proof of concept data generated to date confirms our lead drug candidates’ anti-fibrotic activity in several key organs including the kidneys, the heart, the lungs and the liver. Twenty six million patients in the U.S. alone are believed to suffer from chronic kidney diseases (“CKD”). Patients with severe CKD stages (3 and 4) suffer from a progressive loss of their renal function leading to end-stage renal disease and the need for dialysis or kidney transplant. Cardiovascular complications are the most common cause of death in dialysis patients.

About ProMetic Life Sciences Inc.        

ProMetic Life Sciences Inc. ( is a long established biopharmaceutical company with globally recognized expertise in bioseparations, plasma-derived therapeutics and small-molecule drug development. ProMetic offers its state of the art technologies for large-scale purification of biologics, drug development, proteomics and the elimination of pathogens to a growing base of industry leaders and uses its own affinity technology that provides for highly efficient extraction and purification of therapeutic proteins from human plasma in order to develop best-in-class therapeutics and orphan drugs. ProMetic is also active in developing its own novel small-molecule therapeutic products targeting unmet medical needs in the field of fibrosis, anemia, neutropenia, cancer and autoimmune diseases/inflammation as well as certain nephropathies. Headquartered in Laval (Canada), ProMetic has R&D facilities in the UK, the U.S. and Canada, manufacturing facilities in the UK and commercial activities in the U.S., Canada, Europe, Russia, Asia and Australia.

Forward Looking Statements

This press release contains forward-looking statements about ProMetic’s objectives, strategies and businesses that involve risks and uncertainties. These statements are “forward-looking” because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, ProMetic’s ability to develop, manufacture, and successfully commercialize value-added pharmaceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of ProMetic to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations in ProMetic’s Annual Information Form for the year ended December 31, 2015, under the heading “Risk and Uncertainties related to ProMetic’s business”. As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations. All amounts are in Canadian dollars unless indicated otherwise.

About the Author

Fred Dumais

Fred is responsible for leading Prometic’s investor relations team and is accountable for all global investor relations activity, PR and event management. He joined the company in 2001, and brings nearly twenty years of experience in investor and financial communications, as well as a deep experience of the pharmaceutical industry. He has extensive knowledge of the global financial markets in the US, Europe and his native country of Canada. Fred is a graduate from Concordia University where he gained a BA in Business Communications. He also brings to the role a background in law with a LLB from the University of Québec.

Previous Article
European Commission Grants Orphan Drug Designation To Prometic’s PBI-4050 Drug For The Treatment Of Alström Syndrome
European Commission Grants Orphan Drug Designation To Prometic’s PBI-4050 Drug For The Treatment Of Alström Syndrome

PBI-4050 has been granted an orphan drug designation status for the treatment of Alström Syndrome (“AS”) by...

Next Article
Prometic’s PBI-4050 demonstrates early evidence of efficacy in its Idiopathic Pulmonary Fibrosis (“IPF”) phase 2 clinical trial
Prometic’s PBI-4050 demonstrates early evidence of efficacy in its Idiopathic Pulmonary Fibrosis (“IPF”) phase 2 clinical trial

Early evidence of efficacy of PBI-4050 alone and shown to be very well tolerated whether used alone or in c...